Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

AimMax Therapeutics Inc
Profile last edited on: 10/23/23      CAGE: 8CZ09      UEI: VCBNGNMH78J9

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2017
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4220 Apex Highway Suite 140
Durham, NC 27713
   (919) 797-1146
   N/A
   www.aimmaxrx.com
Location: Single
Congr. District: 04
County: Durham

Public Profile

AimMax Therapeutics management describe what the firm is about as a process by which their personnel engage in the R&D of pharmaceuticals at various stages throughout the development process via a process of in-licensing and/or co-development with strategic partners.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$613,401
Phase II Dollars
$0
Total Awarded
$613,401

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $612,894
Project Title: Optimization and Characterization of Novel Antifungal Peptides
2023 2 NIH $1,306,877
Project Title: Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea
0 1 NIH $306,954
Project Title: Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections

Key People / Management

  Laurene Wang -- Founder and CEO

  Jason Cook -- Senior Research Scientist

  Kara S Keedy -- Head of Anti-Infective Programs

  Derek Nunez -- Chief Medical Officer

  David Pereira -- Head of Chemistry, Discovery and Development

Company News

There are no news available.